

Supplementary Table 4. The patient characteristics for early mortality

Characteristic	Total	Early mortality	Non early mortality	<i>p</i> value
Total	127 (100.0)	36 (28.3)	91 (71.7)	
Age (yr)	83 (80–93)	83 (80–89)	82 (80–93)	0.296
Sex, male	63 (49.6)	19 (30.2)	44 (69.8)	0.400
ECOG PS				0.112
0	2 (1.6)	0 (0.0)	2 (2.2)	
1	19 (15.0)	4 (11.1)	15 (16.5)	
2	54 (42.5)	11 (30.6)	43 (47.3)	
3	36 (28.3)	13 (36.1)	23 (25.3)	
4	16 (12.6)	8 (22.2)	8 (8.8)	
CCI				0.482
≤ 4	34 (26.8)	9 (25.0)	25 (27.5)	
> 4	93 (73.2)	27 (75.0)	66 (72.5)	
ISS				0.533
I	10 (7.9)	1 (2.8)	9 (9.9)	
II	27 (21.3)	7 (19.4)	20 (22.0)	
III	84 (66.1)	27 (75.0)	57 (62.6)	
R-ISS				0.231
I	5 (3.9)	1 (2.8)	4 (4.4)	
II	45 (35.4)	17 (47.2)	28 (30.8)	
III	47 (37)	9 (25.0)	38 (41.8)	
Myeloma type				
Heavy chain				0.786
IgG	79 (62.2)	25 (69.4)	54 (59.3)	
IgA	27 (21.3)	7 (19.4)	20 (22.0)	
IgM	7 (5.5)	2 (5.6)	5 (5.5)	
IgD	1 (0.8)	0 (0.0)	1 (1.1)	
Light chain disease	13 (10.2)	2 (5.6)	11 (12.1)	
Light chain				0.558
Kappa	71 (55.9)	20 (55.6)	51 (56.0)	
Lambda	56 (44.1)	16 (44.4)	40 (44.0)	
CRAB criteria				
Calcium > 11 mg/dL	11 (8.7)	7 (19.4)	4 (4.4)	0.012
Creatinine > 2 mg/dL	32 (25.4)	14 (40.0)	18 (19.8)	0.019
Hemoglobin < 10 g/dL	95 (74.8)	30 (83.3)	65 (71.4)	0.120
Bone disease	85 (68)	23 (67.6)	62 (68.1)	0.560
Lab				
Platelet < 100 × 10 ⁹ /L	32 (25.4)	12 (34.3)	20 (22.0)	0.117
Albumin < 3.5g/dL	85 (66.9)	28 (77.8)	57 (62.6)	0.075
LDH elevation	49 (39.5)	11 (32.4)	38 (42.2)	0.214
High-risk cytogenetic abnormalities	21 (22.3)	3 (11.5)	18 (72.3)	0.097
Chemotherapy	86 (67.7)	13 (36.1)	73 (80.2)	< 0.001

Supplementary Table 4. Continued

Characteristic	Total	Early mortality	Non early mortality	<i>p</i> value
First chemotherapy regimen				0.414
Bortezomib-based	27 (31.4)	2 (15.4)	25 (34.2)	
Lenalidomide-based	17 (19.8)	3 (23.1)	14 (19.2)	
Alkylating agent-based	42 (48.4)	8 (61.5)	34 (46.6)	

Values are presented as number (%) or median (range).

ECOG PS, Eastern Cooperative Oncology Group Performance Status; CCI, Charlson comorbidity index; ISS, International Staging System; R-ISS, Revised International Staging System; Ig, immunoglobulin; LDH, lactate dehydrogenase.